跳至主要内容
临床试验/NCT05486832
NCT05486832招募中不适用

"TARGET Study": Safety and Performance of the Cardiovalve TR Replacement System for Tricuspid Regurgitation

Cardiovalve Ltd.13 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2022年12月9日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
招募中
入组人数
100
试验地点
13
主要终点
Freedom from device or procedure-related adverse events

研究概览

简要总结

The objective of this study is to evaluate the safety and performance of Cardiovalve TR system

详细描述

The study is a multi-center, prospective, single arm study designed to evaluate the safety and performance of the Cardiovalve Tricuspid Valve Replacement System

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 85 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Functional TR ≥3+
  • Symptomatic, NYHA Class II-IVa
  • Patient approved by the Subject Screening Committee

排除标准

  • Cardiac anatomy deemed not suitable for the Cardiovalve TR system
  • Hemodynamic instability
  • Severe right ventricular failure
  • Refractory heart failure requiring advanced intervention

研究组 & 干预措施

Cardiovalve TR replacement Group

Experimental

Cardiovalve TR valve replacement System

干预措施: Cardiovalve TR valve replacement System (Device)

结局指标

主要结局

Freedom from device or procedure-related adverse events

时间窗: 30 days

Freedom from device or procedure-related adverse events

Reduction in TR grade

时间窗: 30 days

Reduction in TR in comparison to baseline

次要结局

  • Six minute walk test(30 days, 6 months, 12 months, annual for five years)
  • KCCQ(30 days, 6 months, 12 months, annual for five years)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (13)

Loading locations...

相似试验